Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib in MET Amplified Metastatic Colorectal Cancer
NCT03592641Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Started Jul 2019; status: terminated.
02
Drugs
savolitinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03592641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03592641.